Lilly first quarter EPS beats consensus
This article was originally published in Scrip
Executive Summary
Eli Lilly's first quarter 2013 earnings show that the company's efforts to manage the impact of generic Zyprexa (olanzapine) are paying off, but investors also recognized that future growth will be tempered by additional patent expirations and pipeline successes or failures.